LaserSight moves to Nasdaq SmallCap:
This article was originally published in Clinica
Laser vision correction company LaserSight is no longer eligible for trading on the Nasdaq National Market and its stock was transferred to the Nasdaq SmallCap Market from August 9. Continued listing on the SmallCap requires that the company's shares close at $1 on or before August 13. It may, however, be eligible for a 180-day grace period if it can demonstrate shareholders' equity of at least $5m, is in compliance with all other requirements and files an application for a new listing and related review. The Winter Park, Florida-based company believes it meets the requirements and intends to file the application on time.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.